Circulating prostaglandin E
Cyclooxygenase-2
Hepatocellular carcinoma
Monoacylglycerol lipase
Prostaglandin E2
Survival
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
21
09
2020
accepted:
17
03
2021
pubmed:
27
3
2021
medline:
14
1
2022
entrez:
26
3
2021
Statut:
ppublish
Résumé
We aimed to explore the activation of monoacylglycerol lipase (MAGL)/cyclooxygenase-2 (COX-2)/prostaglandin E
Identifiants
pubmed: 33768340
doi: 10.1007/s10238-021-00705-z
pii: 10.1007/s10238-021-00705-z
doi:
Substances chimiques
Biomarkers
0
Prostaglandins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-682Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Elsharkawy AM, Mann DA. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46:590–7.
doi: 10.1002/hep.21802
Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:28–44.
doi: 10.1016/j.ctrv.2005.10.004
Habib A, Chokr D, Wan JH, et al. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut. 2019;68:522–32.
doi: 10.1136/gutjnl-2018-316137
Zechner R, Zimmermann R, Eichmann TO, et al. FAT SIGNALS - Lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012;15:279–91.
doi: 10.1016/j.cmet.2011.12.018
Tripathi RKP. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. Eur J Med Chem. 2020;188:111953.
doi: 10.1016/j.ejmech.2019.111953
Tardelli M. Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease. World J Gastroenterol. 2020;26:3577–85.
doi: 10.3748/wjg.v26.i25.3577
Zang S, Ma X, Wu Y, et al. PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol. 2017;63:120–7.
doi: 10.1016/j.humpath.2017.02.018
Cao Z, Mulvihill MM, Mukhopadhyay P, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology. 2013;144:808–17.
doi: 10.1053/j.gastro.2012.12.028
Tardelli M, Bruschi FV, Claudel T, et al. Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. J Lipid Res. 2019;60:1284–92.
doi: 10.1194/jlr.M093369
Tardelli M, Bruschi FV, Fuchs CD, et al. Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis. Hepatology. 2020;71:1750–65.
doi: 10.1002/hep.30929
Zhu W, Zhao Y, Zhou J, et al. Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition. J Hematol Oncol. 2016;9:127.
doi: 10.1186/s13045-016-0361-3
Zhang J, Liu Z, Lian Z, et al. Monoacylglycerol lipase: a novel potential therapeutic target and prognostic indicator for hepatocellular carcinoma. Sci Rep. 2016;6:35784.
doi: 10.1038/srep35784
Lv X, Chen Z, Li S, Xie H. Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells. Onco Targets Ther. 2019;12:4341–9.
doi: 10.2147/OTT.S196822
Tai Y, Zhang LH, Gao JH, et al. Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2. Cancer Manag Res. 2019;11:2831–48.
doi: 10.2147/CMAR.S183376
Chen G, Li X, Yang J, et al. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci. 2016;12:1110–7.
doi: 10.5114/aoms.2016.61916
Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through akt activation: evidence for akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68.
doi: 10.1053/jhep.2003.50380
Li T, Zhong J, Dong X, et al. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway. Oncol Rep. 2016;35:3614–22.
doi: 10.3892/or.2016.4764
Cheng SY, Zhang H, Zhang M, et al. Prostaglandin E2 receptor EP2 mediates snail expression in hepatocellular carcinoma cells. Oncol Rep. 2014;31:2099–106.
doi: 10.3892/or.2014.3074
Xia S, Ma J, Bai X, et al. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Oncol Rep. 2014;32:1521–30.
doi: 10.3892/or.2014.3393
Bai X, Wang J, Guo Y, et al. Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway. Sci Rep. 2014;4:6538.
doi: 10.1038/srep06538
Mayoral R, Fernández-Martínez A, Boscá L, Martín-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis. 2005;26:753–61.
doi: 10.1093/carcin/bgi022
Zhang H, Cheng S, Zhang M, et al. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol. 2014;44:769–80.
doi: 10.3892/ijo.2013.2234
Qu L, Cai X, Xu J, et al. Six long noncoding RNAs as potentially biomarkers involved in competitive endogenous RNA of hepatocellular carcinoma. Clin Exp Med. 2020;20:437–47.
doi: 10.1007/s10238-020-00634-3
Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med. 2020;20:329–37.
doi: 10.1007/s10238-020-00620-9
Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
doi: 10.1016/S0168-8278(12)61409-3
Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–84.
doi: 10.1016/j.jhep.2015.07.004
Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol. 2013;58:956–61.
doi: 10.1016/j.jhep.2013.01.005
Chaud M, Faletti A, de Estrada MB, Gimeno AL, Gimeno MAF. Synthesis and release of prostaglandins D2 and E2 by rat uterine tissue throughout the sex cycle. Effects of 17-β-estradiol and progesterone. Prostaglandins, Leukot Essent Fat Acids. 1994;51:47–50.
doi: 10.1016/0952-3278(94)90177-5
Asselin E, Goff AK, Bergeron H, Fortier MA. Influence of sex steroids on the production of prostaglandins F2α and E2 and response to oxytocin in cultured epithelial and stromal cells of the bovine endometrium. Biol Reprod. 1996;54:371–9.
doi: 10.1095/biolreprod54.2.371
Neong SF, Billington EO, Congly SE. Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: review of pathogenesis and management. Hepatology. 2019;69:2683–95.
pubmed: 30468515